Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants

Co-Founder and CEO Thomas Kledal describes the science behind this platform and program. Plus, how having access to donated kidneys is helping the company with its translational work.